title: Type 2 myocardial infarction: incidence, presentation, treatment and outcome in routine clinical practice.
abstract: OBJECTIVE
  The clinical definition and optimal treatment for myocardial infarction (MI) type 2 (T2MI) are not well established. We assessed differences in presentation, treatment and outcomes of patients with MI type 1 (T1MI) and T2MI.
  
  
  METHODS
  The data of MI patients enrolled in the AMIS Plus cohort with T2MI were compared with T1MI using propensity score matching.
  
  
  RESULTS
  A total of 13 829 patients had T1MI and 1091 (7.3%) T2MI. Patients with T2MI were older, often female, with more risk factors and comorbidities, and less ST segment elevation. After matching for these differences (1091 per group), T2MI patients less often presented with typical chest pain but more frequently with atrial fibrillation (15.6 vs. 4.9%; P < 0.001) and anemia (33.5 vs. 23.3%; P < 0.001) than patients with T1MI. They less frequently received percutaneous coronary interventions (51.1 vs. 76.4%; P < 0.001) and antiplatelet treatment. No differences were found for in-hospital (5.8 vs. 5.6%; OR 1.04; 95% confidence interval 0.72-1.49) and 1-year mortality (11.2 vs. 7.2%; P = 0.38) between matched T2MI and T1MI patients.
  
  
  CONCLUSIONS
  Patients who suffered a T2MI had less typical symptoms, were less aggressively treated with anticoagulants, platelet inhibitors or percutaneous coronary intervention, but had similar complications and mortality to those with T1MI. Patients with T2MI are a heterogeneous group that requires further investigation to better define optimal therapeutic approaches.
authors.affiliation: aAMIS Plus Data Center, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich bDepartment of Cardiology, Swiss Cardiovascular Center, Berne University Hospital, Berne cDivision of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich dCardiovascular Department, La Tour Hospital, Geneva eDivision of Cardiology, Cardiocentro Ticino, Lugano fAMIS Plus, Zurich, Switzerland.
authors.forename: Dragana
authors.initials: D
authors.lastname: Radovanovic
authors.forename: Thomas
authors.initials: T
authors.lastname: Pilgrim
authors.forename: Burkhardt
authors.initials: B
authors.lastname: Seifert
authors.forename: Philip
authors.initials: P
authors.lastname: Urban
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pedrazzini
authors.forename: Paul
authors.initials: P
authors.lastname: Erne
mesh_terms: D054058:Acute Coronary Syndrome / Q000145:classification* / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D016009:Chi-Square Distribution; D015897:Comorbidity; D005260:Female; D054624:Health Status Disparities; D017052:Hospital Mortality; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000145:classification* / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy; D016017:Odds Ratio; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D057216:Propensity Score; D011446:Prospective Studies; D012042:Registries; D012307:Risk Factors; D017678:Sex Distribution; D013557:Switzerland / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors